肝脏硬度对肝细胞癌射频消融疗效的影响

肝脏 ›› 2018, Vol. 23 ›› Issue (6): 478-480.

肝脏硬度对肝细胞癌射频消融疗效的影响

李猛, 皋月娟, 李志艳, 陈敏, 田江克, 汤雨, 周艳贤

100039 北京解放军第三○二医院超声科

收稿日期:2018-01-06 发布日期:2020-04-26
通讯作者: 李志艳,Email:lzyyuer@sina.com
基金资助:
国家自然科学基金(81471680)

Clinical study of the effect of liver stiffness on treatment efficacy of radiofrequency ablation in hepatocellular carcinoma patients

LI Meng, GAO Yue-juan, LI Zhi-yan, CHEN Min, TIAN Jiang-ke, TANG Yu, ZHOU Yan-xian

Department of Ultrasound, 302 Military Hospital of China, Beijing 100039, China

Received:2018-01-06 Published:2020-04-26
Contact: LI Zhi-yan, Email: lzyyuer@sina.com

摘要/Abstract

摘要： 目的研究肝脏硬度对肝细胞癌(HCC)射频消融疗效的影响。方法 2014年10月至2017年2月行超声引导射频消融治疗HCC患者,共106例114个结节。治疗前采用肝纤维化扫描仪(FibroScan)对患者肝脏行硬度测量,根据检测记录,将患者分为高LSM组和低LSM组。统计分析两组患者的疗效差异。结果治疗后1个月复查,高LSM组与低LSM组分别有67和41个结节完全灭活,两组结节完全灭活率分别为94.4%和95.3%(P=0.88);随访期间,高LSM组和低LSM组分别有13个、3个结节发生局部复发,局部复发率分别为16.9%、7.0%;高LSM组和低LSM组患者分别有18例、4例发生肝内复发,肝内复发率分别为28.4%、10.3%,两组间差异均有统计学意义。结论肝脏硬度是HCC射频消融治疗后发生局部复发和肝内复发的影响因素。

关键词: 射频消融, 肝细胞癌, 超声, 瞬时弹性成像

Abstract: Objective To analyze the effect of liver stiffness on treatment efficacy of radiofrequency ablation in hepatocellular carcinoma (HCC) patients.Methods From October 2014 to February 2017, there were 106 patients with 114 nodules receiving ultrasound-guided radiofrequency ablation in our hospital. Liver stiffness measurement (LSM) value was measured by FibroScan before treatment and patients were divided into high-LSM group and low-LSM group with a cutoff value of 17.6 kPa. Differences of complete necrosis rate, local tumor progression rate and intrahepatic recurrence rate between the two groups were analyzed. Results The complete necrosis rates of high-LSM group and low-LSM group were 94.4% and 95.3%, respectively, which showed no statistical difference (P=0.88). The local tumor progression rates and intrahepatic recurrence rates were significantly lower in high-LSM group than those in low-LSM group (16.9% vs. 28.4%, P=0.03 and 7.0% vs. 10.3%, P=0.02, respectively). Conclusion LSM value could be a useful predictor for local tumor progression and intrahepatic recurrence after radiofrequency ablation in HCC patients.

Key words: Radiofrequency ablation, Hepatocellular carcinoma, Ultrasound, Transient elastography

李猛, 皋月娟, 李志艳, 陈敏, 田江克, 汤雨, 周艳贤. 肝脏硬度对肝细胞癌射频消融疗效的影响[J]. 肝脏, 2018, 23(6): 478-480.

LI Meng, GAO Yue-juan, LI Zhi-yan, CHEN Min, TIAN Jiang-ke, TANG Yu, ZHOU Yan-xian. Clinical study of the effect of liver stiffness on treatment efficacy of radiofrequency ablation in hepatocellular carcinoma patients[J]. Chinese Hepatolgy, 2018, 23(6): 478-480.

参考文献

[1] Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol, 2003, 38:200-207.
[2] Wong JS, Wong GL, Chan AW, et al. Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. Ann Surg, 2013, 257:922-928.
[3] Jung KS, Kim SU, Choi GH, et al. Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement (FibroScan). Ann Surg Oncol, 2012, 19:4278-4286.
[4] Ahmed M, Sobiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology, 2014, 273:241-260.
[5] Brener S. Transient elastography for assessment of liver fibrosis and steatosis: an evidence-based analysis. Ont Health Technol Assess Ser, 2015, 15:1-45.
[6] Seo YS, Kim MN, Kim SU, et al. Risk assessment of hepatocellular carcinoma using transient elastography vs. liver biopsy in chronic hepatitis B patients receiving antiviral therapy. Medicine (Baltimore), 2016, 95:e2985.
[7] Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology, 2009, 49:1954-1961.
[8] 陈敏华, S. Nahum Goldberg. 肝癌射频消融—基础与临床. 北京: 人民卫生出版社,1版, 2009:16-23.
[9] Seo JY, Kim W, Kwon JH, et al. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. Liver Int, 2013, 33:884-893.
[10] Kwak MS, Lee JH, Chung GE, et al. Low P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radio frequency ablation therapy. Hepatogastroenterology, 2011, 58:147-152.

[1]	程静, 徐路, 彭素琼. 肝血流超声参数联合外周血vWF-Ag对肝硬化患者食管静脉曲张出血的预测价值[J]. 肝脏, 2020, 25(3): 260-263.
[2]	徐晓鸾, 孟繁坤, 郑颖, 孙丽娟, 李欣. ICG清除试验及肝脏弹性值在肝癌术前的应用研究[J]. 肝脏, 2020, 25(3): 264-266.
[3]	卢君瑶, 王登宇, 尹东林, 白玉盘, 许洁. HBV相关肝细胞癌的临床特征及危险因素分析[J]. 肝脏, 2020, 25(3): 285-287.
[4]	冯文杏, 周小舟, 韩志毅, 孙新锋, 马文峰, 张卫. GALAD模型在诊断HBV相关肝细胞癌中的价值探讨[J]. 肝脏, 2020, 25(3): 291-294.
[5]	冯俊, 常凤玲. 超声造影LI-RADS分类标准在肝细胞癌鉴别及诊断中的应用[J]. 肝脏, 2020, 25(3): 297-299.
[6]	薛志伟, 王伟. Gd-BOPTA肝脏DFCE-MRI与常规MRI在HCC诊断中的对比研究[J]. 肝脏, 2020, 25(3): 306-307.
[7]	原庆会, 何伟. Vimentin在肝细胞癌组织中的表达及其与临床预后的关系[J]. 肝脏, 2020, 25(2): 199-201.
[8]	贾磊, 李豪, 白鸿太, 陈国勇, 魏思东. CD34和Ki67的表达预测肝癌术后复发的风险[J]. 肝脏, 2020, 25(2): 197-198.
[9]	周志莲, 邵春燕, 刘向东. 肝细胞癌行TACE治疗术后并发症的原因分析和处理体会[J]. 肝脏, 2020, 25(2): 191-193.
[10]	夏海英, 陈颖, 陈芳, 邢荣荣, 苏啸. Fibroscan检测肝脂肪变成功率的影响因素及护理策略[J]. 肝脏, 2020, 25(2): 188-190.
[11]	李友学. 三维超声造影对肝癌消融治疗后残留病灶的诊断价值[J]. 肝脏, 2020, 25(2): 175-180.
[12]	王家欢, 李震. 对比经皮射频消融术和经腹腔镜下肝切除术治疗Ⅰa期原发性肝癌的临床效果[J]. 肝脏, 2020, 25(2): 146-148.
[13]	魏媛媛, 田艳红, 李红静, 张浩, 李木松. RNA、lnc-EGFR对肝细胞癌免疫逃避调节的相关性[J]. 肝脏, 2020, 25(2): 142-145.
[14]	杜品清, 刘云国, 胡毅. 肝细胞癌微血管浸润的CT、MRI影像特征及其诊断价值[J]. 肝脏, 2020, 25(2): 138-141.
[15]	张军建, 张矿召. 丙型肝炎病毒NS3非结构蛋白对人胚胎肝细胞L02细胞增殖以及端粒酶活性的研究[J]. 肝脏, 2020, 25(2): 135-137.